HC Deb 15 December 1978 vol 960 cc463-4W
Mr. Pavitt

asked the Secretary of State for Social Services if, in assessing promotional costs in relation to the pharmaceutical price regulation scheme, his Department makes a distinction between materials used for double-blind clinical trials and medicines sent to doctors for pseudo-trials.

Mr. Moyle:

As I indicated in my reply of 5th December—[Vol. 959, c. 617–18.] —the cost of general practitioner clinical trials is not included in sales promotion expenditure in returns under the pharmaceutical price regulation scheme. I am, however, currently reviewing the general question of this type of trial.